Exelixis to cut jobs after prostate cancer drug fails late-stage study
September 01, 2014 at 19:02 PM EDT
Sept 1 (Reuters) - Cancer drug developer Exelixis Inc said on Monday it would cut about 70 percent of its workforce after its experimental prostate cancer drug cabozantinib failed a late-stage study.